Fig. 2: Cell viability of APCs and B16F10 cells after exposure to melittin and α-melittin-NPs.
From: Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
a–c Real-time and dynamic imaging of BMDCs (a), BMDMs (b), and B16F10 cells (c) after incubations with free melittin (5 μM) and α-melittin-NP (10 μM). Green: BMDC, magenta: BMDM, cyan: B16F10. Red indicates PI. BMDCs and BMDMs were isolated from Actb-EGFP C57BL/6 mice in which EGFP is expressed uniformly in all cells except the erythrocytes and hair. Representative images from three independent experiments are shown. All scale bars represent 10 μm. d Evaluation of cellular-binding ability by analyzing the MFI of FITC-α-melittin-NPs in B16F10 cells, BMDCs and BMDMs (n = 3 per group). Incubation time: 3 h. MFI: mean fluorescent intensity. The MFI values were normalized according to minimum in each type of cell. e Representative immunofluorescence imaging of cellular binding of FITC-α-melittin-NPs (10 μM) to B16F10 cells, BMDCs and BMDMs. BMDCs and BMDMs were isolated from mT/mG mice that express a strong red fluorescence protein (tdTomato) in the membrane systems (plasma membrane, lysosome, etc) of all cell types. Incubation time: 3 h. Blue: DAPI, green: FITC-α-melittin-NPs, red: membrane-targeted tdTomato. Representative images from three independent experiments are shown. Scale bar: 5 μm. Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01 and ****P < 0.0001, as analyzed by one-way ANOVA with Bonferroni’s post hoc test (d). Source data are provided as a Source Data file.
